急性髓系白血病靶向凋亡途径治疗的研究进展

Research progress of targeted apoptosis pathway therapy for acute myeloid leukemia

急性髓系白血病是一种血液系统恶性肿瘤,尽管我们对其分子生物学的理解在不断进步,但它的治疗仍是一种挑战。急性髓系白血病的凋亡途径是存在异常的,目前白血病细胞逃避凋亡的不同途径已被作为潜在的治疗靶点,不同方面的几种药物已被开发。一些临床研究显示靶向凋亡药物及其相关联合方案具有较强的抗白血病活性,能够延长患者的总生存期。本文着重讲述靶向不同凋亡途径治疗急性髓系白血病的药物及其相关联合方案的进展情况。

Acute myeloid leukemia is a kind of hematological malignancy.Although our understanding for its molecular biology is constantly improving,its treatment is still a challenge.The apoptosis pathway of acute myeloid leukemia is abnormal.At present,different ways for leukemia cells to escape apoptosis have been used as potential therapeutic targets,and several drugs in different aspects have been developed.Some clinical studies have shown that targeted apoptosis drugs and related combination treatment scheme have stronger anti-leukemia activity and can prolong the total survival duration of patients.This article focuses on the progress of drugs that target different apoptotic pathways in treatment of acute myeloid leukemia and related combination treatment scheme.